Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TNXP 
Tonix Pharmaceuticals Holding Corp (TNXP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: TNXP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $67.67
1 Year Target Price $67.67
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.89% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 190.19M USD | Price to earnings Ratio 0.06 | 1Y Target Price 67.67 |
Price to earnings Ratio 0.06 | 1Y Target Price 67.67 | ||
Volume (30-day avg) 2 | Beta 1.82 | 52 Weeks Range 6.76 - 130.00 | Updated Date 11/14/2025 |
52 Weeks Range 6.76 - 130.00 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 279.15 |
Earnings Date
Report Date 2025-11-10 | When - | Estimate -3.31 | Actual -3.6975 |
Profitability
Profit Margin - | Operating Margin (TTM) -1005.08% |
Management Effectiveness
Return on Assets (TTM) -35.94% | Return on Equity (TTM) -64.99% |
Valuation
Trailing PE 0.06 | Forward PE - | Enterprise Value 19521385 | Price to Sales(TTM) 22.33 |
Enterprise Value 19521385 | Price to Sales(TTM) 22.33 | ||
Enterprise Value to Revenue 1.9 | Enterprise Value to EBITDA 0.94 | Shares Outstanding 11776542 | Shares Floating 11771831 |
Shares Outstanding 11776542 | Shares Floating 11771831 | ||
Percent Insiders 0.03 | Percent Institutions 17.79 |
Upturn AI SWOT
Tonix Pharmaceuticals Holding Corp
Company Overview
History and Background
Tonix Pharmaceuticals Holding Corp. was founded in 2007. It focuses on developing pharmaceutical products for central nervous system (CNS) conditions, including pain, psychiatric, and addiction disorders. It has undergone several restructuring and strategic shifts.
Core Business Areas
- Neurology and Psychiatry: Focuses on developing treatments for conditions such as fibromyalgia, PTSD, and other CNS disorders. Their main drug targets are pain reduction and mental health.
- Infectious Diseases: Developing therapies to prevent and treat infectious diseases, including potential vaccines and antiviral medications.
Leadership and Structure
The leadership team includes Dr. Seth Lederman (CEO), Jessica Morris (CFO), and other executives focused on research and development, clinical operations, and regulatory affairs. The organizational structure is typical of a biotechnology company, with departments focusing on drug discovery, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Tonmya (TNX-102 SL): This is Tonix's lead product candidate, designed for the management of fibromyalgia. Currently in clinical trials. No market share or revenue yet due to pre-commercial status. Competitors include Lyrica (Pfizer) and Cymbalta (Eli Lilly) along with generic options.
- TNX-2100: An investigational COVID-19 vaccine candidate. Still in preclinical development. Competitors include Pfizer/BioNTech, Moderna, Novavax.
- TNX-1900: An oxytocin nasal spray being developed for Prader-Willi syndrome. Still in early stage trials. Few direct competitors exist.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The CNS and infectious disease markets are particularly large and growing due to increasing prevalence of these conditions.
Positioning
Tonix is a clinical-stage pharmaceutical company focusing on underserved markets and novel therapeutic approaches. Its competitive advantage lies in its focus on specific niche areas within CNS and infectious diseases. However, its lack of approved products is a disadvantage.
Total Addressable Market (TAM)
The TAM for fibromyalgia and other CNS disorders is substantial, estimated to be in the billions of dollars annually. The TAM for COVID-19 vaccines is also significant, though market conditions have shifted. Tonix is positioning itself to capture a share of these markets pending successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting unmet needs
- Experienced leadership team
- Proprietary technology platforms
- Strong intellectual property portfolio
Weaknesses
- Lack of approved products and revenue stream
- Dependence on successful clinical trial outcomes
- High cash burn rate
- Dilution to shareholders to fund operations
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Government funding for research and development
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
- Adverse events during clinical trials
Competitors and Market Share
Key Competitors
- LLY
- PFE
- VRX
Competitive Landscape
Tonix faces significant competition from larger, more established pharmaceutical companies with greater resources and approved products. Tonix's advantage lies in its focus on specific niche areas and novel therapeutic approaches, but its lack of approved products is a major disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Tonix's historical growth is marked by progress in clinical trials and drug development, but not by revenue generation.
Future Projections: Future growth depends heavily on the success of its clinical trials and eventual regulatory approvals. Analyst estimates are highly speculative due to the inherent risks in drug development.
Recent Initiatives: Recent initiatives include advancing clinical trials for Tonmya, expanding its vaccine development program, and seeking strategic partnerships.
Summary
Tonix Pharmaceuticals is a high-risk, high-reward clinical-stage company with a focus on novel therapies for CNS disorders and infectious diseases. The company's future hinges on the success of its clinical trials, particularly for Tonmya. While its focus on unmet needs and innovative approaches is promising, it faces significant financial and regulatory challenges. Significant dilution of existing investors is a constant threat.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Company Website
- Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in pharmaceutical companies carries significant risk. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tonix Pharmaceuticals Holding Corp
Exchange NASDAQ | Headquaters Chatham, NJ, United States | ||
IPO Launch date 2012-05-10 | Co-Founder, President, CEO & Chairman Dr. Seth Lederman M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://www.tonixpharma.com |
Full time employees 81 | Website https://www.tonixpharma.com | ||
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.